HomeInsightsStock Comparison

Ind Swift Ltd vs Syncom Formulations India Ltd Stock Comparison

Ind Swift Ltd vs Syncom Formulations India Ltd Stock Comparison

Last Updated on: Aug 06, 2025

Key Highlights

  • The Latest Trading Price of Ind-Swift Ltd is ₹ 16.18 as of 06 Aug 10:44.
  • The P/E Ratio of Ind-Swift Ltd is 0 as of March 2022 .The P/E Ratio of Syncom Formulations (India) Ltd is 46.2 as of March 2022.
  • The Market Cap of Ind-Swift Ltd is ₹ 60.61 crore as of March 2022 .The Market Cap of Syncom Formulations (India) Ltd is ₹ 916.79 crore as of March 2022.
  • The revenue of Ind-Swift Ltd for the Mar '25 is ₹ 426.19 crore as compare to the Dec '24 revenue of ₹ 122.96 crore. This represent the growth of 246.61% The revenue of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 155.83 crore as compare to the Dec '24 revenue of ₹ 131.57 crore. This represent the growth of 18.44%.
  • The ebitda of Ind-Swift Ltd for the Mar '25 is ₹ 278.4 crore as compare to the Dec '24 ebitda of ₹ 9.98 crore. This represent the growth of 2689% The ebitda of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 24.7 crore as compare to the Dec '24 ebitda of ₹ 18.77 crore. This represent the growth of 31.59%.
  • The net profit of Ind-Swift Ltd changed from ₹ 2.36 crore to ₹ 256.6 crore over 8 quarters. This represents a CAGR of 942.73% The net profit of Syncom Formulations (India) Ltd changed from ₹ 4.4 crore to ₹ 17.69 crore over 8 quarters. This represents a CAGR of 100.51% .
  • The Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2024 . This represents a CAGR of -100.00% over 3 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ind-Swift Ltd

  • Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
  • The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
  • The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
  • The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

About Syncom Formulations (India) Ltd

  • Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
  • The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
  • Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
  • Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

Ind-Swift Ltd News Hub

News

Ind-Swift Ltd leads gainers in 'B' group

Jayaswal Neco Industries Ltd, Aarti Drugs Ltd, Sampann Utpadan India Ltd and Soma Textiles...

Read more

15 Jul 2025 12:15

News

Ind-Swift to discuss results

Ind-Swift will hold a meeting of the Board of Directors of the Company on 25 June 2025. Po...

Read more

20 Jun 2025 10:07

News

Ind-Swift to convene board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 30 May 2025. Pow...

Read more

24 May 2025 17:38

News

Ind-Swift to conduct board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 11 February 2025...

Read more

07 Feb 2025 16:29

News

Ind-Swift EGM scheduled

Ind-Swift announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

21 Jan 2025 14:05

News

Ind-Swift to conduct board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 14 November 2024...

Read more

08 Nov 2024 16:42

Syncom Formulations (India) Ltd News Hub

News

Syncom Formulations (India) to table results

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

04 Aug 2025 11:23

News

Syncom Formulations (India) schedules board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

14 May 2025 14:06

News

Syncom Formulations (India) to convene board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

05 Nov 2024 14:12

News

Syncom Formulations (India) schedules AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 17:48

News

Syncom Formulations (India) to hold AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 10:30

News

Syncom Formulations gains after Q1 PAT rises over 73% YoY

Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total e...

Read more

13 Aug 2024 13:37

SWOT Analysis Of Syncom Formulations (India) Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Ind-Swift Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Syncom Formulations (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Ind-Swift Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ind-Swift Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Ind-Swift Ltd or Syncom Formulations (India) Ltd?

Market cap of Ind-Swift Ltd is 89 Cr while Market cap of Syncom Formulations (India) Ltd is 1,707 Cr

What are the key factors driving the stock performance of Ind-Swift Ltd and Syncom Formulations (India) Ltd?

The stock performance of Ind-Swift Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Ltd and Syncom Formulations (India) Ltd?

As of August 6, 2025, the Ind-Swift Ltd stock price is INR ₹16.47. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹18.17.

How do dividend payouts of Ind-Swift Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Ind-Swift Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions